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Abstract
Background: Acute exposure to prostaglandin E2 (PGE2) activates EP receptors in sensory neurons which triggers
the cAMP-dependent protein kinase A (PKA) signaling cascade resulting in enhanced excitability of the neurons.
With long-term exposure to PGE2, however, the activation of PKA does not appear to mediate persistent
PGE2-induced sensitization. Consequently, we examined whether homologous desensitization of PGE2-mediated
PKA activation occurs after long-term exposure of isolated sensory neurons to the eicosanoid.
Methods: Sensory neuronal cultures were harvested from the dorsal root ganglia of adult male Sprague-Dawley
rats. The cultures were pretreated with vehicle or PGE2 and used to examine signaling mechanisms mediating
acute versus persistent sensitization by exposure to the eicosanoid using enhanced capsaicin-evoked release of
immunoreactive calcitonin gene-related peptide (iCGRP) as an endpoint. Neuronal cultures chronically exposed to
vehicle or PGE2 also were used to study the ability of the eicosanoid and other agonists to activate PKA and
whether long-term exposure to the prostanoid alters expression of EP receptor subtypes.
Results: Acute exposure to 1 μM PGE2 augments the capsaicin-evoked release of iCGRP, and this effect is blocked
by the PKA inhibitor H-89. After 5 days of exposure to 1 μM PGE2, administration of the eicosanoid still augments
evoked release of iCGRP, but the effect is not attenuated by inhibition of PKA or by inhibition of PI3 kinases.
The sensitizing actions of PGE2 after acute and long-term exposure were attenuated by EP2, EP3, and EP4 receptor
antagonists, but not by an EP1 antagonist. Exposing neuronal cultures to 1 μM PGE2 for 12 h to 5 days blocks the
ability of PGE2 to activate PKA. The offset of the desensitization occurs within 24 h of removal of PGE2 from the
cultures. Long-term exposure to PGE2 also results in desensitization of the ability of a selective EP4 receptor agonist,
L902688 to activate PKA, but does not alter the ability of cholera toxin, forskolin, or a stable analog of prostacyclin
to activate PKA.
Conclusions: Long-term exposure to PGE2 results in homologous desensitization of EP4 receptor activation of PKA,
but not to neuronal sensitization suggesting that activation of PKA does not mediate PGE2-induced sensitization
after chronic exposure to the eicosanoid.
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Background
Prostaglandin E2 (PGE2) is a critical inflammatory medi-
ator that contributes to acute and chronic pain by
directly altering the sensitivity of sensory neurons to
noxious and non-noxious stimuli [1, 2]. This eicosanoid
is produced and released in the periphery by acute tissue
injury, and its production is sustained during chronic
inflammation [3–5]. Acute sensitization of sensory neu-
rons by PGE2 occurs through activation of EP receptors
that couple to the Gαs/3′,5′-cyclic adenosine monopho-
sphate (cAMP) signaling pathway [6]. Acute exposure to
PGE2 increases the production of cAMP in sensory
neurons [7, 8], and inhibition of protein kinase A (PKA)
attenuates prostaglandin-induced hyperalgesia [9] and
prostaglandin-induced increases in sodium currents [10,
11] and TRPV1 channel activity [12].
The signaling for chronic prostaglandin-mediated
sensitization has been historically quite puzzling, since it is
well established that chronic exposure to agonists can
desensitize G-protein-coupled receptors (GPCRs) [13, 14].
However, an important characteristic of prostaglandin-
induced hypersensitivity is that it does not downregulate
with long-term exposure to the eicosanoid. For example, in
patients with chronic inflammatory conditions, drugs that
prevent the synthesis of prostaglandins (non-steroidal anti-
inflammatory drugs, NSAIDs) are effective in reducing both
acute and chronic hypersensitivity [15–17], suggesting that
prostaglandins maintain their ability to sensitize sensory
neurons through a mechanism that is not subject to
classical GPCR downregulation. In animal models of in-
flammation or in animals chronically exposed to PGE2, the
ability of the eicosanoid to enhance nociception does not
diminish, but subsequent administration of PGE2 results in
a stronger and more prolonged hyperalgesia [18–20]. This
phenomenon, termed “hyperalgesic priming” [21], can be
modeled in isolated sensory neurons where acute exposure
to PGE2 sensitizes neurons to various stimuli [1, 7, 22] and,
like their in vivo counterparts, the sensitizing actions of ei-
cosanoids are not diminished by chronic exposure [23, 24].
Although the cellular mechanisms that account for
persistent sensitization of sensory neurons by PGE2 are
not known, one potential explanation for maintaining
sensitization is through effector switching. For example,
after an inflammatory insult, which increases production
of prostaglandins and other inflammatory mediators,
hyperalgesia induced by subsequent injection of PGE2 is
not attenuated by inhibiting PKA but is blocked by inhibi-
tors of other signaling effectors [20, 25]. After 14 daily
injections of PGE2 into the rat hindpaw, hyperalgesia-
induced by PGE2 injection is attenuated by PKA and
protein kinase C inhibitors, not just by inhibiting PKA
[18]. In sensory neurons from normal animals, the ability
of PGE2 to augment ATP-induced current is blocked by
PKA inhibitors, whereas in neurons from inflamed rats,
the PGE2 effect is abolished only after inhibition of both
PKA and protein kinase C (PKC) [26]. Furthermore, when
isolated sensory neurons are maintained in culture with
the inflammatory mediator, nerve growth factor (NGF),
the ability of PGE2 to sensitize the neurons is not blocked
by inhibition of PKA, whereas in neurons grown without
NGF, PKA inhibition is effective [27]. These data suggest
that PKA is not the major effector of persistent PGE2-in-
duced sensitization of sensory neurons.
To date, there are few, if any, studies that directly exam-
ine whether chronic exposure to PGE2 downregulates the
activation of PKA and, if so, whether this downregulation is
specific for PGE2-induced activation. Consequently, using
sensory neuronal cultures, we examined whether long-term
exposure to PGE2 causes a loss in the ability of the eicosa-
noid to activate PKA. Our results show that chronic expos-
ure of sensory neuronal cultures to PGE2 or an EP4
receptor agonist results in a complete but reversible loss in
the ability of PGE2 to activate PKA. Furthermore, both
acute sensitization and that which is observed after long-
term exposure to PGE2 show the same profile of EP recep-
tor activation suggesting that the downregulation is not sec-
ondary to alterations in EP receptor expression or function.
This functional downregulation of PKA is homologous
since activation of PKA by carbaprostacyclin, forskolin, or
cholera toxin is not altered by chronic exposure to PGE2.
Methods
Materials
Fetal bovine serum, F-12 media, glutamine, penicillin-
streptomycin, and fungizone were obtained from Invitro-
gen, Carlsbad, CA, whereas Normocin was purchased
from InvivoGen, San Diego, CA. The small molecule PKA
inhibitor H-89, the PKA pseudosubstrate inhibitor frag-
ment 5-24 (PKI 5-24), Kemptide, poly-D-lysine, laminin,
collagenase, 5-fluoro-2′-deoxyuridine, uridine, capsaicin,
1-methyl-2-pyrrolidinone (MPL), cholera toxin (CTX),
TG4-155, and other routine chemicals were purchased
from Sigma-Aldrich, St. Louis, MO. PGE2, carbaprostacy-
clin (cPGI2), L902688, ONO-8711, ONO-AE3-208, rabbit
polyclonal antibodies for EP receptors, and cAMP enzyme
immunoassay kits were purchased from Cayman Chemi-
cals, Ann Arbor MI. L-798,106 was purchased from Santa
Cruz, Dallas, TX. 3-isobutyl-1-methylxanthine (IBMX)
and rat calcitonin gene-related peptide (CGRP) were
obtained from Tocris Bioscience, Minneapolis, MN, and
(Tyr27)-α-CGRP (27–37) was acquired from Bachem,
Torrance, CA. [γP32]-ATP was purchased from PerkinEl-
mer, Waltham, MA. Protease inhibitor cocktail Set III,
EDTA-free, and phosphatase inhibitor cocktail set I were
obtained from EMD Millipore, Darmstadt, Germany. LI-
COR blocking buffer, TO-PRO-3, and Rockford secondary
antibodies were obtained from LI-COR Biosciences,
Lincoln, NE. Prestained protein size markers, precast
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SDS-PAGE gels, iScript reverse transcription kits, and
PVDF membranes were obtained from BioRad, Hercules,
CA. RNA STAT-60 was purchased from Tel-test, Inc.,
Friendswood, TX. Normal donkey serum was from
Jackson ImmunoResearch Laboratories, West Grove, PA.
NGF was purchased from Envigo, Indianapolis, IN. PGE2,
cPGI2, L902688, forskolin, and capsaicin were initially dis-
solved in MPL and then diluted to the desired concentra-
tion with phosphate-buffered saline (PBS). Cholera toxin
was dissolved in a buffer consisting of 0.05 M Tris buffer,
pH 7.5, 0.2 M NaCl, 0.003 M NaN3, and 0.001 M sodium
EDTA as per Sigma-Aldrich product information. Other
drugs were diluted in PBS. The Animal Care and Use
Committee at Indiana University School of Medicine, In-
dianapolis, IN, approved all procedures used in these
studies.
Cell culture
Sensory neuronal cultures were prepared as described
previously with minor modifications [28]. Male Sprague-
Dawley rats weighing approximately 145 g (Harlan,
Indianapolis, IN) were euthanized by CO2 asphyxiation,
and the dorsal root ganglia (DRG) were dissected from
the entire spinal column and then incubated in F-12
media containing collagenase (1.25 mg/ml) for 1 hour at
37 °C. The collagenase-containing F-12 media was aspi-
rated and replaced with fresh F-12 containing Normocin,
and the DRG were mechanically dissociated using a fire-
polished glass pipette. Cell culture wells were pre-coated
with poly-D-lysine and laminin, and approximately
15,000 cells were plated into each well of 24-well culture
plates, approximately 30,000 cells were plated into each
well of 12-well culture plates, or approximately 60,000
cells were plated into each well of 6-well cultures plates.
Cells were maintained in F-12 media supplemented with
10 % fetal bovine serum, 2 mM glutamine, 100 μg/ml
Normocin, 50 μg/ml penicillin, 50 μg/ml streptomycin,
50 μM 5-fluoro-2′-deoxyuridine and 150 μM uridine in
saturated humidity, and 3 % CO2 incubator at 37 °C.
Cultures were grown in the absence or presence of 30
ng/ml exogenously added NGF, as indicated, and the
media was changed every other day. For experiments in-
volving long-term exposure to PGE2, media with fresh
PGE2 was changed every 24 h.
Neuropeptide release
For release experiments, neuronal cultures grown for 8–
12 days were washed with HEPES buffer (25 mM
HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 mM CaCl2,
1 mM MgCl2, 3.3 mM D-glucose, and 0.1 % bovine
serum albumin, pH 7.4) at 37 °C. Cultures were incu-
bated for 10 min in 0.4 ml HEPES buffer in the presence
and absence of vehicle or drugs to determine resting re-
lease and then for 10 min in 0.4 ml of HEPES buffer
containing 30 nM capsaicin in the presence or absence of
vehicle or drugs to stimulate peptide release. A third incu-
bation with HEPES buffer alone for 10 min was performed
to confirm the return to resting release, which occurs in all
experiments. At the end of the release protocol, the cells
were hypotonically lysed by incubation for 10 min in
0.4 ml of 0.1 M HCl to extract total remaining CGRP in
the culture. Release and content samples were aliquoted
and assayed for immunoreactive CGRP (iCGRP) by radio-
immunoassay as previously described [29]. Release data are
presented as percent of total iCGRP content/10 min.
Measurement of PKA activity
On the day of the experiment, the F-12 media in the cul-
tures was replaced with drug-free fresh media and main-
tained for 20 min in the CO2 incubator. The cultures
were then exposed to different drug treatments at 37 °C
for 10 min, followed by two washes in ice-cold PBS. Cul-
tures were lysed in 250 μl of ice-cold lysis buffer that
contained β-glycerophsophate 25 mM, EGTA 1.25 mM,
MgCl2 10 mM, dithiothrietol 1 mM, ×2 protease inhibi-
tors cocktail set III, NaCl 100 mM, and 1 % Triton-X
100. Cells were scraped, and the buffer was snap-frozen
in liquid nitrogen, stored at −80 °C, and assayed within
24 h. After thawing, cell lysates were briefly sonicated
followed by centrifugation at 16,100×g for 30 min at 4 °
C. For each sample, 10 μl of the supernatant was added
to 40 μl of the PKA activity assay buffer containing β-
glycerophosphate 25 mM, EGTA 1.25 mM, MgCl2
10 mM, NaCl 100 mM, dithiothrietol 0.5 mM, ×2 phos-
phatase inhibitor cocktail set I, ATP 100 μM, [γP32]-ATP
(3 μCi/40 μl), and Kemptide 10 μM. The reaction was
incubated at 30 °C for 5 min. At the end of the 5 min in-
cubation, 20 μl of this reaction mixture was spotted on
P81 filter paper discs (Whatman, GE Healthcare Life
Sciences) and washed five times (5 min per wash) in
15 mM phosphoric acid. The bound radioactivity was
measured using Cerenkov counting in a scintillation
counter. PKA activity was measured as a function of
incorporation of radioactive phosphate into Kemptide, a
peptide that is selectively phosphorylated by PKA [30, 31].
Under these assay conditions, PKA-induced phosphoryl-
ation exhibits a linear relationship (r2 = 0.99) over time for
up to 10 min (data not shown) indicating that the sub-
strates, ATP and Kemptide, are not limiting during the
5 min of incubation used in our studies. PKA activity was
measured in the presence or absence of the selective
pseudosubstrate inhibitor, PKI 5-24 (5 μM) and the dif-
ference represented as selective PKA activity. The PKA
data are calculated as the ratio of the treatment-activated
PKA minus nonspecific activity (determined in the
presence of PKI 5-24) divided by the maximum PKA ac-
tivity (using 10 μM cAMP) minus its nonspecific activity
(determined in the presence of cAMP and PKI 5-24).
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Measure of cAMP
Growth medium was aspirated from the culture dishes, and
cells were washed twice with 0.4 ml of HEPES buffer con-
taining 2 mM IBMX. After washing, cells were incubated in
0.4 ml HEPES buffer containing IBMX for 20 min in the ab-
sence or presence of vehicle, 1 μM PGE2, or 1 μM forskolin.
The HEPES buffer was aspirated, and the cells were scraped
into 300 μl 0.1 N HCl, boiled for 5 min, and centrifuged at
1200×g for 15 min. The supernatant was decanted, frozen,
and lyophilized. Samples were resuspended, and immunore-
active cAMP was assayed using enzyme immunoassay kits
from Cayman Chemical according to kit instructions. Data
were expressed as pmol of cAMP per well.
RNA isolation and quantitative real-time RT-PCR
To extract RNA, the growth medium was removed and
RNA STAT-60 was added directly to the wells. The cell
lysate was transferred to a RNase- and DNase-free 1.5 ml
Eppendorf tube and allowed to sit for 5 min at room
temperature before the addition of chloroform (0.2 ml/
1 ml RNA STAT-60). The samples were vortexed briefly,
stored at room temperature for 5 min, and centrifuged at
12,000×g for 15 min at 4 °C. The aqueous layer containing
RNA was transferred to a fresh RNase- and DNase-free
Eppendorf tube, and the RNA was precipitated overnight
at room temperature by the addition of 0.5 ml isopropa-
nol. The RNA precipitate was pelleted by centrifugation at
12,000×g for 15 min at 4 °C. The supernatant was
removed, and the remaining RNA pellet was washed with
1 ml of 75 % ethanol. The mixture was centrifuged at
7500×g for 10 min at 4 °C, the ethanol removed, and the
pellet allowed to dry until no moisture was evident in the
tube. The RNA pellet was resuspended in 20 μl of water
treated with diethyl pyrocarbonate (DEPC water), and a 1/
20 dilution of the RNA was quantitated using a BioRad
SmartSpec 3000.
Following RNA isolation, approximately 1.5 μg of RNA
product, 2 units of DNase I, and reaction buffer (20 mM
Tris-HCl, 2 mM MgCl2, 50 mM KCl) were incubated at
room temperature for 15 min. The DNase was inactivated
by incubation at 65 °C in the presence of 2.5 mM EDTA.
Approximately 1.0 μg of total RNA was reverse transcribed
using the iScript cDNA synthesis kit. The reaction mix
included 15 μl of RNA (1.0 μg), 4 μl of iScript Reaction
mix, and 1 μl of iScript Reverse Transcriptase. The reaction
was incubated at 25 °C for 5 min, followed by 42 °C for
30 min, and 85 °C for 5 min. Reverse transcription products
were diluted and real-time PCR performed on an ABI
Prism 7700 Sequence Detector, using SYBR Green Ampli-
taq Master Mix (Thermo Fisher Scientific). The primers
were designed to be selective for each of the PGE2 receptor
subtypes and splice variants, and for GAPDH, which was
used as an endogenous control. Primer sequences were as
follows: EP1F: AACAGGCGGTAACGGCACAT, EP1R:
CGCAGTCTGCCTGCAACCT (NM_013100; amplicon
size 110 bp); EP3CF: TCGCTGAACCAGATCTTGGAT,
EP3CR: CTGGAGACAGCGTTTGCTACC (D16443;
amplicon size 91 bp); EP4F: CCCTCCTATACCTGC-
CAGACC, EP4R: CATGCGTACCTGGAAGCAAA (NM_
032076; amplicon size 68 bp); and GAPDHF: TTCA
ATGGCACAGTCAAGGC, GAPDHR: TCCTGGAAGA
TGGTGATGGG (X02231; amplicon size 70 bp). Amplifi-
cation was performed using universal PCR parameters.
After completion of 40 cycles, the temperature was ramped
from 60 to 95 °C over 20 min to establish a dissociation
curve in each PCR experiment to verify that the fluores-
cence signal was due to a single amplicon amplification.
The relative standard curve method was used to quan-
titate relative changes in messenger RNA (mRNA)
expression. Standard curves from 1- to 100-fold dilu-
tions of the experimental control starting cDNA were
prepared for both the genes of interest and for GAPDH.
For each experimental sample (two replicates of two dif-
ferent dilutions), the amount of the gene of interest and
GAPDH was determined by the appropriate standard
curve. These concentrations were corrected for dilution
and normalized to the amount of cDNA in the vehicle-
treated control group.
Li-Cor quantitative immunohistochemistry
Neuronal cultures grown in 24-well culture plates were
treated as indicated. Immediately after treatment, the buf-
fer containing drugs was aspirated and 4 % formalin in
PBS was placed on the cells for 20 min. The fixed cells
were then rinsed five times with PBS containing 0.5 % Tri-
ton X-100 for 5 min each rinse. Cells were treated with
Triton X-100 and then blocked using a 1:1 dilution of the
Li-Cor blocking buffer in PBS for at least 2 h. Primary
antibodies to the EP1, EP3, and EP4 receptors were di-
luted in 50 % Li-Cor blocking buffer solution in PBS at
1:50–1:250. Cells were incubated in primary antibody
overnight and then rinsed five times with PBS containing
0.5 % Tween-20. Some wells of cells were not incubated
with primary antibody to determine the nonspecific ac-
tions of the secondary antibody, i.e., background staining.
The secondary antibody, Rockford goat anti-rabbit anti-
body, conjugated to IRDye™ 800CW was diluted in the 1:1
Li-Cor blocking buffer solution in PBS at 1:800. TO-PRO-
3, a nucleic acid stain that emits signal detected on the
700 channel of the infrared scanner, was added to the sec-
ondary antibody at a concentration of 1:2000. Cells were
incubated in the secondary antibody and TO-PRO-3 for
2 h. This portion of the experiment was performed in the
dark, as the infrared dyes can photobleach in a manner
similar to fluorescent dyes. The secondary antibody was
then removed, and the cells were washed five times with
PBS containing 0.5 % Tween-20. The plates of cells were
allowed to air-dry and were scanned for infrared signal.
Malty et al. Journal of Neuroinflammation  (2016) 13:181 Page 4 of 17
The plates were scanned using the Odyssey Imager
infrared scanner. The scan intensity was set at 5 for both
the 700- and 800-nm channels, and the scan quality was
set at a resolution of 169 μm for medium quality scans.
Both the 700 channel and the 800 channel were scanned
simultaneously. Background signal was subtracted from
the wells that were incubated with primary antibody. The
signal intensity at the 800 channel (EP signal) was normal-
ized to the most intense EP well for each experimental
group to control for differences in staining intensities be-
tween different plates. The percent of maximum EP inten-
sity was then divided by the signal at the 700 channel
(nucleic acid signal) to correct for possible differences in
cell density. Data were expressed as percent of the max-
imal EP immunoreactivity: TO-PRO-3 immunoreactivity.
Data analysis
Data are expressed as mean ± the standard error of the
mean (SEM) for at least three independent experiments
from separate harvests. Protein kinase A activity data were
analyzed using one-way ANOVA followed by Bonferroni’s
post hoc test or using Student’s t test as indicated. For
cAMP content, mRNA, and protein expression, a paired
Student t test was used to determine significant differences
between control and treated wells. A p value of <0.05 was
considered statistically significant in all experiments.
Results
Prostaglandin E2 and agents that increase production of
cAMP augment PKA activity in sensory neuronal culture
Previous studies have shown that exposing sensory neurons
in culture to PGE2 or prostaglandin I2 (PGI2) increases the
production of cAMP [6, 7]. Furthermore, inhibitors of PKA
attenuate the acute sensitizing actions of PGE2 suggesting
that sensitization is mediated by activation of PKA [11, 12,
26, 32]. Because cAMP has multiple downstream effectors,
we measured whether exposing sensory neuronal cultures
to increasing concentrations of PGE2 would directly in-
crease PKA activity (see the “Methods” section for details).
When sensory neuronal cultures were exposed to PGE2 for
10 min and PKA activity determined in cell lysates, treat-
ment with PGE2 resulted in a concentration-dependent in-
crease in PKA activity (Fig. 1a). The relationship between
the log concentration of PGE2 and PGE2-induced PKA
activity was fit to a sigmoidal curve with a correlation coef-
ficient of 0.95 and an EC50 of 0.8 μM. The normalized PKA
activity increased from 0.06 ± 0.01 for cultures treated with
0.1 μM PGE2 to 0.78 ± 0.10 for cultures exposed to 10 μM
PGE2. Concentrations of 0.3, 1, 3, and 10 μM PGE2 all
produced a significant increase in PKA activity compared
to vehicle (Fig. 1a).
Previously, we showed that the acute sensitizing actions
of PGE2 on sensory neurons are mediated, in part, by acti-
vation of the EP4 receptors, which are coupled to Gαs [6].
Furthermore, increasing cAMP production via exposure
of sensory neurons to cPGI2, which increases activation of
Gαs through the IP receptor; forskolin, which is a direct
activator of adenylyl cyclase; or CTX, which ADP-
ribosylates Gαs, also sensitizes sensory neurons [7]. Conse-
quently, we examined whether these various drug treat-
ments enhance PKA activity in our neuronal cultures.
Exposing the cultures to 1 μM PGE2 increases PKA activ-
ity ~ninefold above that seen in vehicle-treated cells
(0.01 % MPL; Fig. 1b), whereas 300 nM of the EP4 recep-
tor agonist, L902688, increased PKA activity ~3.5-fold and
1 μM cPGI2 increased activity ~ninefold (Fig. 1b). Activa-
tion of adenylyl cyclases with 1 μM forskolin or exposure
of cultures overnight to 1 μM CTX to activate Gαs also
significantly increased PKA activity ~five- and ~ninefold
compared to vehicle, respectively (Fig. 1b). We also exam-
ined whether activation of β-adrenergic receptors with
isoproterenol would increase PKA activity since this drug
when injected into the hindpaw of rats augments nocicep-
tive behaviors [33]. Exposing neuronal cultures to 10 μM
isoproterenol produced a small increase in PKA (1.2-fold)
above vehicle-treated cultures (Fig. 1b). Although signifi-
cant, only modest PKA activation was observed following
exposure to a range of isoproterenol concentrations (1–
100 μM). The ratios of isoproterenol-activated PKA to
total PKA activity were 0.12 ± 0.01, 0.10 ± 0.004, 0.11 ±
0.01, 0.13 ± 0.01, and 0.11 ± 0.003 for 1, 3, 10, 30, and
100 μM, respectively (data not shown).
PGE2-induced augmentation of capsaicin-evoked iCGRP
release is maintained after long-term exposure to the
eicosanoid but is not mediated by activation of PKA
Since the acute sensitizing action of PGE2 on sensory neu-
rons is mediated through activation of EP receptors that
are part of the GPCR family [6, 34], chronic exposure to
PGE2 should result in tolerance or desensitization to the
sensitizing effects of this prostanoid. Previous studies,
however, suggest that the ability of PGE2 to sensitize sen-
sory neurons does not downregulate after chronic expos-
ure to the eicosanoid [17, 24]. Consequently, we examined
whether the ability of PGE2 to augment capsaicin-evoked
release of iCGRP from sensory neurons downregulated
after long-term exposure to the prostanoid and whether
this sensitizing action was attenuated by the PKA inhibi-
tor, H-89. When sensory neurons in culture were exposed
to 30 nM capsaicin, release of iCGRP increased approxi-
mately threefold from a basal level of 3.4 ± 0.7 % of total
content/10 min to 10.5 ± 1.3 % of total content/10 min
(Fig. 2a). Treating cells with 1 μM PGE2 significantly aug-
mented the capsaicin-evoked release to 15.6 ± 1.4 % of
total content/10 min (Fig. 2a). Although exposure to
10 μM H-89 did not alter basal or capsaicin-stimulated re-
lease of iCGRP, it did block the ability of PGE2 to augment
capsaicin-evoked release (Fig. 2a).
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To examine the effects of long-term exposure to PGE2,
we treated sensory neuronal cultures with 1 μM PGE2 for
5 days. For these studies, we replaced the culture media
with media containing fresh PGE2 every 24 h since
previous studies demonstrated that PGE2 levels are main-
tained after 24 h in culture [35]. When neuronal cultures
were treated with 1 μM PGE2 for 5 days prior to examining
iCGRP release and the cells re-exposed to 1 μM PGE2 for
20 min, the eicosanoid significantly increased the capsaicin-
evoked release from a control level of 6.2 ± 0.4 to 11.6 ±
0.6 % of total content/10 min (Fig. 2b) demonstrating that
long-term exposure to PGE2 does not downregulate the
sensitizing actions of the prostanoid. Exposing sensory
neuronal cultures to 1 μM PGE2 for 5 days did not alter the
total content of iCGRP. Total peptide content in neuronal
cultures exposed to vehicle for 5 days was 486 ± 58 fmol/
well, whereas in cultures exposed to PGE2 for 5 days
content was 540 ± 67 fmol/well. Thus, using enhancement
of iCGRP release as an endpoint of neuronal sensitization,
long-term exposure to PGE2 did not downregulate the
sensitizing actions of the prostanoid. Although H-89
prevented the acute sensitizing effects of PGE2, PGE2-in-
duced sensitization after long-term exposure to PGE2 was
not blocked by pretreating the cultures with 10 μM H-89
(Fig. 2b). In the presence of 10 μM H-89 alone, capsaicin-
evoked release of iCGRP was 8.5 ± 0.7 % of total content/
10 min, whereas release from cells treated with 10 μM H-
89 and 1 μM PGE2 was 11.3 ± 0.5 % of total content/
10 min. These data support the notion that sensitization
of sensory neurons by PGE2 after chronic exposure to the
prostanoid is not dependent on the activation of PKA.
Since PGE2-induced sensitization is maintained after
long-term exposure to the drug (Fig. 2b), and since acute
exposure to the eicosanoid increases cAMP production
[7], we measured cAMP levels directly to address the
question of whether exposing neuronal cultures to 1 μM
PGE2 for 5 days would alter the ability of the prostanoid
to augment the production of cAMP. In neuronal cul-
tures exposed to vehicle for 5 days, a 10-min treatment
with 1 μM PGE2 significantly increased the content of
cAMP from 68 ± 7 to 183 ± 40 pmol/ml (Fig. 2c). In cul-
tures exposed to 1 μM PGE2 for 5 days, the content of
Fig. 1 Prostaglandin E2 and other activators of cAMP production increase PKA activity in sensory neuronal cultures. a Each point represents
mean ± SEM of PKA activity normalized to total PKA after 10-min exposure to various concentrations of PGE2 from 4 to 6 independent harvests of
cells maintained in the absence of added NGF. Asterisks indicate a statistically significant increase in PKA activity compared to the vehicle-treated
control using one-way ANOVA followed by Bonferroni’s post hoc test. b Each column represents the mean ± SEM of PKA activity normalized to
total PKA after a 10-min exposure to vehicle (V), PGE2, the EP4 receptor agonist, L902688, cPGI2, forskolin, CTX, or isoproterenol (Iso) as indicated.
An asterisk indicates a statistically significant difference between PKA activation by each treatment compared to its respective vehicle control
using Student’s t test
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cAMP after acute treatment with vehicle was 61 ± 4 pmol/
ml and the cAMP content in cells re-exposed to PGE2
was 76 ± 10 pmol/ml. These values were not significantly
different from cAMP content in cells treated with vehicle
for 5 days. In contrast, the ability of forskolin to increase
cAMP content was not significantly different in cultures
exposed for 5 days to vehicle (530 ± 34 pmol/ml) or to
1 μM PGE2 (501 ± 46 pmol/ml).
Acute PGE2-induced sensitization and persistent
sensitization after long-term exposure to the eicosanoid
are mediated by the same EP receptor subtypes
The data presented above suggest that the maintenance
of PGE2 sensitization following chronic exposure to the
prostanoid may be mediated by alternate EP receptors
which couple to different G-proteins and activate alter-
nate downstream signaling pathways. To examine this
possibility, we measured mRNA for the EP1, EP3C, and
EP4 receptors. We chose to study these receptor subtypes
since our previous work suggests that EP3C and EP4
receptors contribute to acute sensitization in isolated
sensory neurons [6]. Furthermore, acute sensitization by
PGE2 has been proposed to be mediated through activa-
tion of EP1 receptors [36]. Six days after harvesting,
sensory neuronal cultures were exposed to 1 μM PGE2 or
vehicle for 24 h, and then total RNA was isolated from the
treated cells and reverse transcribed to cDNA. Exposing
cultures to PGE2 for 24 h did not significantly alter the
Fig. 2 The PGE2-induced increase of capsaicin-evoked iCGRP release from sensory neurons is attenuated by H-89 after acute exposure to the
eicosanoid but not after long-term exposure. a, b Each column represents the mean ± SEM of iCGRP release as percent of total iCGRP content
per well of cells maintained in the absence of added NGF. Lightly shaded columns indicate basal release whereas dark-shaded columns represent
capsaicin-stimulated release of iCGRP. Cultures were treated with vehicle (a) or 1 μM PGE2 (b) for 5 days and then washed and acutely exposed
to 1 μM PGE2 for 20 min in the absence or presence of 10 μM H-89, as indicated. An asterisk indicates a statistically significant difference between
capsaicin-stimulated iCGRP release after exposure to vehicle versus after a 10-min exposure to PGE2 (1 μM) using one-way ANOVA followed by
Bonferroni’s post hoc test. c Each column represents the mean ± SEM of cAMP content. The left panel represents cAMP content from cells
exposed to vehicle for 5 days, whereas the right panel represents cAMP content from cells exposed to PGE2 (1 μM) for 5 days. Cultures were
washed and then re-exposed for 10 min to vehicle (open columns), 1 μM PGE2 (light gray columns), or 1 μM forskolin (dark gray columns).
An asterisk indicates a statistically significant difference from vehicle using one-way ANOVA followed by Bonferroni’s post hoc test
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amounts of mRNA for any of the EP receptors examined:
EP1, EP3C, and EP4 (Fig. 3a). The levels of mRNA for the
EP1 receptor normalized to mRNA for GAPDH were
0.95 ± 0.05 in control cells and 1.10 ± 0.26 after a 24-h
treatment with PGE2. Levels of mRNA for EP3C and EP4
were 0.99 ± 0.14 and 1.11 ± 0.05 in control cells and
0.81 ± 0.07 and 1.03 ± 0.09, respectively, in cells treated
with PGE2. Similar results were observed from neuronal
cultures exposed to PGE2 for 5 days. In these cultures as
in cultures treated for 24 h, long-term exposure to 1 μM
PGE2 did not significantly alter mRNA to EP1, EP2, EP3,
or EP4 receptors compared to cells treated with vehicle
for 5 days (data not shown).
We also determined whether a 24 h exposure to PGE2
would alter the expression of EP receptor proteins using
quantitative immunohistochemistry (see the “Methods”
section). Analogous to the observations of mRNA
expression, long-term exposure of sensory neurons to
PGE2 did not alter EP receptor protein levels (Fig. 3b).
The EP1 immunoreactivity in control wells was 84 ± 7 %,
whereas immunoreactivity was 74 ± 9 % of the maximal
signal after treatment. A 24 h exposure of sensory neu-
rons to PGE2 did not alter total EP3 immunoreactivity;
the control value of EP3 immunoreactivity was 78 ± 7 %,
whereas the EP3 immunoreactivity value was 79 ± 7 % of
maximal after a 24 h exposure to PGE2. Similarly, there
was no change in EP4 immunoreactivity. Intensity values
for EP4 protein were 83 ± 12 and 87 ± 4 % of maximal in
the absence and presence of long-term treatment with
PGE2, respectively (Fig. 3b). Together, the real-time PCR
and quantitative immunohistochemistry data suggest
that a 24 h exposure of sensory neurons in culture to
PGE2 does not alter the expression of EP receptors.
To identify the EP receptor subtypes that contribute to
PGE2-induced sensitization, we used the selective EP
receptor inhibitors ONO-8711, TG4-155, L798,106, and
ONO-AE3-208 to block EP1, EP2, EP3, or EP4 receptor
subtypes, respectively. In sensory neuronal cultures that
were exposed to vehicle for 5 days, pretreating with 30
or 100 nM of the EP2 receptor antagonist, TG4-155; the
EP3 receptor antagonist, L798,106; or the EP4 receptor
antagonist, ONO-AE3-208, blocked the PGE2-induced
augmentation of capsaicin-stimulated release of iCGRP
(Fig. 4a). Exposure to the antagonists in the absence of
PGE2 did not alter basal or capsaicin-stimulated release
of iCGRP (Fig. 4a). In contrast, pretreating cultures with
the EP1 receptor antagonist, ONO-8711, did not attenu-
ate the PGE2-induced increase in capsaicin-stimulated
Fig. 3 Twenty-four hour exposure of sensory neurons in culture to 1 μM PGE2 does not alter the expression of EP receptors as measured by
real-time RT-PCR. a Dorsal root ganglia were harvested and cultured for 6 days in media containing 30 ng/ml NGF. After 24-h treatment with
vehicle (lightly shaded columns) or 1 μM PGE2 (dark-shaded columns), the RNA was isolated and reverse transcribed to cDNA for analysis by PCR.
Each column represents the mean ± SEM of the ratio of EP receptor mRNA to GAPDH mRNA from three independent harvests of cells. b Each
column represents the mean ± SEM of the % maximum immunoreactivity for EP receptors normalized to TO-PRO-3 immunoreactivity in
neuronal cultures after 24 h treatment with vehicle (lightly shaded columns) or 1 μM PGE2 (dark-shaded columns) for six to eight wells of cells
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release (Fig. 4a). After 5-day exposure to PGE2, re-
exposure to the prostanoid caused sensitization that was
completely inhibited by the EP4 receptor antagonist and
to a lesser degree by EP2 and EP3 receptor antagonists,
but not by the EP1 receptor antagonist (Fig. 4b). To-
gether, these results show that chronic exposure to PGE2
does not change the EP receptor profile that mediates
sensitization by the eicosanoid.
Long-term exposure to PGE2 downregulates PKA activity
induced by the prostanoid
Although PGE2-induced sensitization of sensory neurons
after long-term exposure to the eicosanoid does not ap-
pear to be PKA dependent, the question remains whether
the ability of PGE2 to increase PKA activity downregulates
with chronic exposure to the prostanoid. To examine this
directly, we determined whether 1 μM PGE2 could
increase PKA activity in neuronal cultures treated with
the eicosanoid for 5 days. As observed in previous experi-
ments, when sensory neuronal cultures were exposed to
vehicle for 5 days and then challenged with 1 μM PGE2
for 10 min, the eicosanoid caused a significant increase in
PKA activity from 0.06 ± 0.003 to 0.52 ± 0.1 (Fig. 5a). In
contrast, when cultures are exposed to 1 μM PGE2 for
5 days and then re-exposed to the eicosanoid, there was
no significant increase in PKA activity (PKA activity was
0.07 ± 0.0003, Fig. 5a). Increasing the concentration of
PGE2 10-fold caused a small, but not significant, increase
in PKA activity (0.14 ± 0.01) in cultures exposed to PGE2
for 5 days (Fig. 5a). The total specific PKA activity after
Fig. 4 Acute PGE2-induced sensitization and persistent sensitization after long-term exposure to the eicosanoid are mediated by the same EP
receptor subtypes. Each column represents the mean ± SEM of capsaicin-stimulated release of iCGRP as percent of total iCGRP content per
well/10 min in cultures maintained in the absence of added NGF and preexposed to vehicle (a) or to 1 μM PGE2 for 5 days (b). After
pretreatment, cultures were acutely exposed to vehicle (lightly shaded columns) or to 1 μM PGE2 (dark-shaded columns) for 20 min in
the absence or presence of EP receptor antagonists, as indicated. An asterisk indicates a statistically significant difference between
capsaicin-stimulated release of iCGRP after vehicle versus after PGE2 using one-way ANOVA followed by Bonferroni’s post hoc test
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exposure to 10 μM cAMP was not affected by the long-
term exposure to PGE2 suggesting that the downregula-
tion of PGE2-activated PKA was not caused by any
decrease in the overall kinase activity (Fig. 5b).
Since activation of EP4 receptors on sensory neurons
mediates the sensitizing actions of PGE2 [6, 34], we exam-
ined whether long-term exposure to the EP4 receptor
agonist L902688 or to PGE2 downregulated the increase
in PKA activity produced by activation of EP4 receptors.
We chose to use L902688 in the current experiments
because it has an approximate 7000–32,000 higher affinity
of binding to EP4 when compared to other EP receptor
subtypes [37]. When neuronal cultures were exposed to
300 nM L902688 for 10 min, there was a significant
increase in PKA activity from 0.04 ± 0.007 to 0.12 ± 0.01
(Fig. 5c). In contrast, when neuronal cultures were treated
with L902688 for 5 days, re-exposure to the agonist did
not significantly increase PKA activity above control levels
(Fig. 5c). Likewise, when neuronal cultures were treated
with 1 μM PGE2 for 5 days, exposing the cultures to
L902688 for 10 min did not increase PKA activity (0.04 ±
0.01 and 0.06 ± 0.01 vehicle and L902688, respectively).
Together, these data suggest that chronic activation of
EP4 receptors results in a loss of their ability to couple to
PKA signaling in response to an agonist.
Time course of the onset and offset of desensitization of
the PGE2-induced activation of PKA in sensory neuronal
cultures after chronic exposure
The data presented above clearly show that exposing sen-
sory neurons to PGE2 for 5 days abolishes the subsequent
PGE2-induced activation of PKA. To ascertain the duration
of exposure to PGE2 that is necessary to downregulate
prostanoid-induced activation of PKA and to determine
whether this desensitization is reversible, we examined
PGE2-induced PKA activation after cultures were exposed
to PGE2 for various lengths of time. To determine the time
course for desensitization, sensory neuronal cultures were
exposed to either vehicle for the last 5 days in culture or to
1 μM PGE2 for the last 3, 6, 12, 72 h or 5 days in culture
(Fig. 6a, top panel). In all instances, PKA activity was deter-
mined after cells were maintained in culture for 12 days.
Three and 6 h exposures of neuronal cultures to PGE2
resulted in a reduction in the ability of PGE2 to activate
Fig. 5 Exposing sensory neuronal cultures to PGE2 or to the EP4 receptor agonist L902688 for 5 days desensitizes the agonist-induced increase
in PKA activity. a Each column represents the mean ± SEM of the treatment-stimulated PKA activity normalized to total PKA activity from cultures
grown in the absence of added NGF and treated with vehicle or PGE2 (1 μM) for 5 days as indicated. Cultures were washed and then re-exposed
for 10 min to vehicle (open columns), 1 μM PGE2 (closed columns) or 10 μM PGE2 (hatched column). b Each column represents mean ± SEM of total
specific activity of PKA after exposure to 10 μM cAMP from cultures treated with vehicle or PGE2 (1 μM) for 5 days as indicated. Cultures were
washed then re-exposed for 10 min to vehicle (open columns) or 1 μM PGE2 (closed columns). c Each column represents the mean ± SEM of the
treatment-stimulated PKA activity normalized to total PKA activity from cultures treated with vehicle, 300 nM L902688, or PGE2 (1 μM) for 5 days
as indicated. Cultures were washed and then re-exposed for 10 min to vehicle (open columns) or 300 nM L902688 (closed columns). An asterisk
indicates a statistically significant difference from vehicle using one-way ANOVA followed by Bonferroni’s post hoc test
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PKA by approximately 50 % (Fig. 6a). After a 12 h expos-
ure, the PGE2-induced PKA activity is reduced by 80 %,
whereas maximal inhibition is observed after 3 days of ex-
posure (Fig. 6a). To examine whether the desensitization
was reversible, sensory neurons in culture were exposed to
vehicle for 36 h or to 1 μM PGE2 for 36, 33, 24, or 12 h
and then to vehicle for 0, 3, 12, or 24 h, respectively (Fig. 6b,
top panel), and PKA activity was measured. All cells were
maintained in culture for 12 days. Exposure of sensory neu-
rons to 1 μM PGE2 for 36 h resulted in desensitization of
PGE2-induced activation of PKA (Fig. 6b), an effect we also
observed after 72 h and 5 days of treatment with the eicosa-
noid (Fig. 6a). Three hours after the PGE2 is removed, a re-
exposure to the eicosanoid did not augment PKA activity
(Fig. 6b). In contrast, 12 and 24 h after removal of PGE2,
PKA activation by re-exposure to the eicosanoid recovered
to approximately 42 and 78 % of PGE2-activated PKA in
naïve cultures (Fig. 6b). Thus, downregulation of the PGE2-
induced activation of PKA is reversible and not secondary
to loss of cell viability after chronic exposure to PGE2.
Homologous desensitization of PKA signaling after long-
term exposure to PGE2
Classical GPCR desensitization is mediated by receptor
uncoupling from the cognate heterotrimeric G-protein and
the downstream signaling pathway [13, 38]. Consequently,
in sensory neurons exposed to PGE2 for 5 days, it is
possible that the EP receptors are no longer coupled to the
Gαs/adenylyl cyclase/PKA pathway. If receptor uncoupling
mediates the loss of PGE2-induced activation of PKA, then
bypassing the receptor by directly activating Gαs or adenylyl
cyclases should increase PKA activity even after long-term
exposure to PGE2. To test this, we examined the effects of
CTX or forskolin on PKA activity after long-term exposure
of sensory neuronal cultures to PGE2. When neuronal
cultures treated with vehicle for 5 days were exposed to
1.5 μg/ml CTX overnight, the PKA activity increased from
0.06 ± 0.007 (vehicle) to 0.46 ± 0.01 (Fig. 7a). In a similar
manner, when cultures were exposed to PGE2 for 5 days,
CTX increased PKA activity from 0.05 ± 0.003 (vehicle) to
0.46 ± 0.02 (Fig. 7a). When neuronal cultures treated with
vehicle for 5 days were exposed to 1 μM forskolin for
20 min, the activator of adenylyl cyclases significantly in-
creased PKA activity from 0.06 ± 0.01 to 0.28 ± 0.04
(Fig. 7b). In cultures treated with 1 μM PGE2 for 5 days,
exposure to forskolin increased PKA activity from 0.05 ±
0.01 to 0.27 ± 0.04 (Fig. 7b). Thus, the downregulation of
PGE2-activated PKA appears to result from the uncoupling
between PGE2 and the PKA signaling pathway at the recep-
tor level.
To determine whether the desensitization of the
PGE2-induced PKA activation is heterologous with PGI2,
Fig. 6 Time course of the onset and offset of desensitization of the PGE2-induced activation of PKA in sensory neuronal cultures after chronic
exposure to the eicosanoid. Each column represents the mean ± SEM of PKA activity normalized to total PKA activity for various times of
exposure to 1 μM PGE2 or after removal of 1 μM PGE2. a Cultures were pretreated with vehicle (open column) or 1 μM PGE2 (hatched columns)
for the times indicated in the time line in the top portion of the figure. b Cultures were pretreated with vehicle (open column) or PGE2 (hatched
columns) for the times indicated in the time line in the top portion of the figure, and then, the PGE2 is removed and cells assayed at the times
indicated. An asterisk indicates a statistically significant difference between PGE2-treated sensory neuronal cultures and vehicle-treated cultures
using one-way ANOVA followed by Bonferroni’s post hoc test
Malty et al. Journal of Neuroinflammation  (2016) 13:181 Page 11 of 17
we treated sensory neuronal cultures with vehicle or 1 μM
PGE2 for 5 days and examined PKA activity after acute ex-
posure to the stable analog of prostacyclin, cPGI2 [39].
We chose to examine this eicosanoid since it increases
cAMP levels and sensitizes sensory neurons through acti-
vation of another GPCR, the IP receptor [7, 40]. In neur-
onal cultures treated with vehicle for 5 days, a 10-min
exposure to 1 μM cPGI2 significantly increased PKA activ-
ity from 0.06 ± 0.004 to 0.544 ± 0.04. In an analogous
manner, cPGI2 increased the PKA activity from 0.05 ±
0.002 to 0.48 ± 0.05 in neuronal cultures exposed to 1 μM
PGE2 for 5 days (Fig. 7c). These data support the notion
that the desensitization observed to PGE2-induced activa-
tion of PKA after long-term administration of the prosta-
noid is homologous.
Previous studies have shown that PKA can phosphor-
ylate the β-adrenergic receptor and this can result in
desensitization [41]. In an analogous manner, activation of
PKC is associated with desensitization of IP receptors [42]
and thromboxane receptors [43]. Consequently, after
long-term exposure to PGE2, activation of PKA and/or
PKC might result in phosphorylation and uncoupling of
the EP receptors from their cognate G-proteins. To exam-
ine this, we treated sensory neurons in culture for 12 h
with 1 μM PGE2 in the absence and presence of 10 μM
H-89 or 1 μM BIM-I to block PKA or PKC activities, re-
spectively, and then examined the effects of an acute chal-
lenge with PGE2. When neuronal cultures were treated for
12 h with vehicle in the absence or presence of H-89 or
BIM-I, exposing the cultures to 1 μM PGE2 for 10 min
Fig. 7 Five-day exposure of sensory neuronal cultures to PGE2 does not produce heterologous desensitization. Each column represents the
mean ± SEM of the treatment-stimulated PKA activity normalized to total PKA activity in cultures exposed to vehicle for 5 days or PGE2
(1 μM) for 5 days as indicated. a Cultures were washed and then re-exposed for 10 min to vehicle (open columns) or CTX (1.5 μg/ml)
overnight (shaded columns). b Cultures were washed and then re-exposed for 10 min to vehicle (open columns) or 1 μM forskolin for
20 min (shaded columns). c Cultures were washed and then re-exposed for 10 min to vehicle (open columns) or 1 μM cPGI2 (shaded
columns) for 20 min. An asterisk indicates statistically significant difference from vehicle using one-way ANOVA followed by Bonferroni’s post hoc test.
d The left panel represents PKA activity from cells exposed to vehicle for 12 h in the absence or presence of 10 μM H-89 or 1 μM BIM-I as indicated,
while the right panel represents PKA activity from cells exposed to PGE2 (1 μM) for 12 h in the absence or presence of 10 μM H-89 or 1 μM BIM-I as
indicated. After washing, the cells were re-exposed to vehicle (open columns) or 1 μM PGE2 (shaded and hatched columns) for 10 min. Asterisks indicate
statistically significant differences in cells acutely exposed to vehicle versus cells exposed to PGE2. Crosses represent statistically significant differences in
cells preexposed for 12 h to vehicle versus those exposed for 12 h to PGE2. Statistical analysis was performed using one-way ANOVA followed by
Bonferroni’s post hoc test
Malty et al. Journal of Neuroinflammation  (2016) 13:181 Page 12 of 17
caused a significant (~10-fold) increase in PKA activity
compared to cells not exposed to the prostanoid (Fig. 7d).
In contrast, in cultures exposed to 1 μM PGE2 for 12 h in
the absence or presence of H-89 or BIM-I, re-exposure to
the eicosanoid did not significantly increase PKA activity
above basal levels (Fig. 7d). In cultures treated with PGE2
for 12 h and re-exposed to vehicle, the PKA activity was
0.06 ± 0.01, whereas with re-exposure to PGE2, the activity
was 0.14 ± 0.02. In cultures treated with PGE2 and H-89
or PGE2 and BIM-I for 12 h, the PKA activity was
0.19 ± 0.02 or 0.16 ± 0.02 after re-exposure to the eicosa-
noid, respectively (Fig. 7d). These findings suggest that
desensitization of the PGE2-induced activation of PKA
after long-term exposure to the prostanoid is not medi-
ated by PKA or PKC-induced phosphorylation of EP
receptors.
Acute PGE2-induced sensitization and persistent
sensitization after long-term exposure to the eicosanoid
are not mediated by activation of PI3 kinases
The data presented above show that both acute and per-
sistent sensitization of sensory neurons by PGE2 are medi-
ated by activation of the same EP receptor subtypes but
that sensitization after chronic exposure to PGE2 is not
dependent on activation of PKA. Since previous work has
shown that binding of PGE2 to EP4 receptors activates
phosphoinositide 3-kinase (PI3K) signaling under different
conditions [44] and that inhibiting PI3 kinases attenuates
inflammatory pain behaviors [45, 46], we examined
whether a pan inhibitor of PI3 kinases would attenuate
acute or persistent PGE2-induced sensitization. In sensory
neuronal cultures treated with vehicle for 5 days, exposing
neuronal cultures to 1 or 3 μM LY294002 prior to and
throughout exposure to capsaicin did not attenuate the
ability of 1 μM PGE2 to augment stimulated iCGRP
release (Fig. 8). In a similar manner, when sensory neurons
were treated with 1 μM PGE2 for 5 days, then re-exposed
to PGE2 neither 1 nor 3 μM LY294002 significantly altered
the eicosanoid-induced increase in capsaicin-stimulated
release of iCGRP.
Discussion
The results presented here demonstrate for the first time
that long-term exposure of sensory neuronal cultures to
PGE2 results in a downregulation in the ability of the
eicosanoid to activate PKA. This downregulation occurs
rapidly with a significant loss of PKA activation within 3 h
of exposure to 1 μM of the agonist and a complete loss
within 72 h. Furthermore, it is reversible since within 24 h
after removal of PGE2 from the neuronal cultures, the
ability of PGE2 to increase PKA activity is fully restored.
Long-term exposure of neuronal cultures to PGE2, how-
ever, does not diminish total PKA activity in the cells or
the ability of CTX, which activates Gαs through ADP ribo-
sylation, or forskolin, which activates adenylyl cyclases, to
increase PKA activity. Exposing neuronal cultures to the
selective EP4 receptor agonist L902688 also activates
PKA, and a cross desensitization is observed with this
agonist in neuronal cultures exposed to PGE2 for 5 days.
This cross desensitization supports the notion that EP4
receptors are critical mediators of sensitization by PGE2.
This observation is further substantiated by the finding
that the EP4 receptor selective antagonist is capable of
blocking sensitization caused by acute exposure to PGE2
Fig. 8 Acute PGE2-induced sensitization and persistent sensitization after long-term exposure to the eicosanoid are not mediated by activation of
PI3 kinases. Each column represents the mean ± SEM of capsaicin-stimulated release of iCGRP as percent of total iCGRP content per well/10 min
in cultures maintained in the absence of added NGF and preexposed to vehicle for 5 days (left panel) or to 1 μM PGE2 for 5 days (right panel).
After long-term exposure, cultures were acutely exposed to vehicle (lightly shaded columns) or to 1 μM PGE2 (dark-shaded columns) for 20 min in
the absence or presence of LY294002, as indicated. An asterisk indicates a statistically significant difference between capsaicin-stimulated release
of iCGRP after vehicle versus after PGE2 using one-way ANOVA followed by Bonferroni’s post hoc test
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and by re-exposure to PGE2 after long-term incubation
with the eicosanoid.
The importance of PKA as an effector mediating acute
sensitization of sensory neurons induced by PGE2 is well
established. Increasing levels of cAMP in sensory
neurons or exposure to cAMP analogs mimics the sensi-
tizing actions of PGE2 in that the second messenger aug-
ments transmitter release from sensory neurons [7],
increases the number of action potentials generated by
various stimuli [47], sensitizes small unmyelinated sen-
sory fibers to heat [48], increases TRPV1 channel activity
[12], increases sodium current in sensory neurons [10,
11], and reduces potassium currents [49]. Inhibitors of
PKA block hyperalgesia induced by PGE2 [50] and at-
tenuate the acute sensitizing actions of PGE2 on sensory
neurons [11, 12, 51, 52]. Although PKA is a critical ef-
fector of sensitization in sensory neurons after acute ex-
posure to prostaglandins, it does not appear to be a major
effector of persistent sensitization. Exposing the sensory
neurons in culture to 1 μM PGE2 for 5 days does not alter
the ability of the prostanoid to augment the capsaicin-
stimulated release of the neuropeptide, CGRP from the
neurons. With acute exposure to PGE2, the augmentation
of transmitter release is blocked by pretreatment with the
PKA inhibitor H-89. This compound has an IC50 for
inhibition of PKA in the nanomolar range [53], and at the
concentration we used, H-89 completely inhibits PKA acti-
vation in our cultures. Unlike the acute sensitizing actions
of PGE2, however, in neurons pretreated with PGE2 for
5 days, H-89 does not block the sensitizing effects of PGE2.
These data provide a mechanism to account for the obser-
vations in animal models that PGE2-induced sensitization
does not downregulate with chronic exposure [54] and that
after inflammation or chronic exposure to PGE2, the
hyperalgesia produced by this prostanoid is not blocked by
inhibitors of PKA [18, 20, 25].
Long-term exposure to PGE2 did not downregulate the
ability of cPGI2 to activate PKA in sensory neurons, dem-
onstrating that the PGE2-induced desensitization is hom-
ologous with respect to EP receptors. This finding is
somewhat unexpected since both EP and IP receptors are
expressed on sensory neurons and PGI2 produces hyper-
algesia [55] and sensitization of sensory neurons through
activation of the cAMP transduction cascade in a manner
analogous to that of EP receptors [7, 40]. The lack of
cross-desensitization, however, suggests that the PGE2-in-
duced downregulation is not caused by activation of the
second messenger-activated kinases, a mechanism which
underlies heterologous desensitization [38, 56]. This is
consistent with our observations that downregulation of
PGE2-induced activation of PKA is not attenuated in
neuronal cultures preexposed to 10 μM H-89 or to 1 μM
BIM-I for 12 h during the exposure to PGE2. This concen-
tration of H-89 is sufficient to totally inhibit PKA activity
in the cultures, as well as the purified catalytic subunit of
PKA in vitro (data not shown), and blocks the ability of
acute PGE2 to sensitize the neurons. The concentration of
BIM-I used in our experiments is sufficient to inhibit ac-
tivity of classic and novel PKCs [57]. Therefore, it is logical
to conclude that neither the two PKA isoforms PKA-I and
PKA-II, which are inhibited by H-89 [58, 59], nor the clas-
sic or novel PKCs mediate the desensitization induced by
long-term exposure to PGE2.
One interesting observation in the current work is that
10 μM isoproterenol only increases PKA activity modestly
compared to 1 μM PGE2, cPGI2, forskolin, 1.5 μg/ml chol-
era toxin, or 300 nM L902688. Moreover, isoproterenol
concentrations from 1 to 10 μM did not cause an appre-
ciable difference in PKA activation, suggesting a lack of a
concentration-response relationship. One possible explan-
ation for the low levels of PKA activation by isoproterenol
is that phosphodiesterase (PDE) activity could increase the
breakdown of cAMP in the subcellular compartment in
which PKA is localized [60, 61] since we did not include a
PDE inhibitor in our assay buffer. Much evidence shows
that scaffolding proteins, e.g., A-kinase anchor proteins
(AKAPs), can maintain adenylyl cyclase, PKA, and PDE in
close proximity, thus creating a highly localized, selective,
and controlled signaling complex [62–64] which suggests
that breakdown of cAMP could be a variable in controlling
PKA activity. It seems unlikely, however, that this could ac-
count for the difference in PKA activation by isoproterenol
versus PGE2 since previous reports indicated that activa-
tion of PKA by PGE2 is also subject to PDE suppression
via degradation of cAMP [65, 66]. Moreover, PKA activity
induced by either PGE2 (1 μM) or isoproterenol (10 μM)
was assayed under the same experimental conditions.
Thus, whether PKA-activation is subject to PDE suppres-
sion or not, we observed that isoproterenol is at least two
orders of magnitude less potent than PGE2 in activation of
PKA in isolated adult rat sensory neuronal cultures.
In the current experiments, we show that exposing the
cultures to PGE2 for 5 days prevents a subsequent treat-
ment with PGE2 from significantly increasing cAMP levels.
This observation confirms previous work [24, 67, 68] and
suggests that chronic exposure to PGE2 causes a downreg-
ulation of EP receptors or that the EP receptors are no
longer effectively coupled to Gαs. However, reduction of EP
receptor expression cannot explain the loss of PGE2-in-
duced cAMP production or PKA activation following long-
term exposure to the eicosanoid, since it is evident from
our data that neither EP receptor mRNA nor protein was
significantly reduced after long-term exposure to PGE2. It
is important to note that increases in cAMP that are
sufficient to activate PKA are highly compartmentalized,
through interaction with multiple AKAPs [69–71]. Conse-
quently, the measure of total cAMP content in tissues may
not reflect the functional effects of the second messenger.
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We have previously shown that a 24 h exposure of sen-
sory neuronal cultures to PGE2 significantly reduces the
maximal receptor binding (Bmax) for the eicosanoid [24].
A similar decrease in Bmax of PGE2 occurs in the dorsal
spinal cord after inflammation, and this effect is blocked by
NSAIDs, suggesting it is secondary to prostaglandin pro-
duction [24]. These data and our current finding that PKA
activation is significantly downregulated after a 12-h expos-
ure to PGE2 suggest that prolonged exposure to PGE2 re-
sults in downregulation of surface expression of EP
receptors, presumably through internalization by the G-
protein receptor kinase (GRK) and β-arrestin machinery
[72, 73]. Despite the decrease in receptor binding, the abil-
ity of PGE2 to sensitize sensory neurons is not diminished
and this is not likely due to a shift from EP receptors linked
to Gαs to those linked to Gαq since a selective EP1 receptor
antagonist does not block acute or persistent sensitization
by PGE2. Furthermore, other investigators have shown that
inflammation or exposure to PGE2 results in a modest in-
crease in the expression of EP4 receptors on the plasma
membrane in sensory neurons [34, 74, 75], although the
reasons for the differences between our results and their
findings remain to be determined. Consequently, it is un-
likely that changes in receptor expression could account for
a loss of the ability of PGE2 to activate PKA while maintain-
ing the ability to sensitize the neurons. A more likely ex-
planation is that after chronic PGE2, the signaling pathway
mediating PGE2-induced sensitization switches from Gαs to
other heterotrimeric G-proteins, such as Gαq/11, or Gα12/13
in a manner analogous to that observed with β-adrenergic
receptors [76]. In the case of the EP4 receptors, studies in
heterologous expression systems have shown that the re-
ceptor can couple to Gαs and Gαi/o under different condi-
tions [77, 78]. Moreover, there is precedent to suggest that
EP4 receptors may signal through Gβγ [79, 80]. In both
cases, however, it is thought that PI3K relays the signal
from either Gαi/o or Gβγ to downstream signaling pathways
[44]. Nevertheless, LY294002 did not attenuate PGE2-in-
duced sensitization after acute or long-term exposure to
the eicosanoid, suggesting that PI3K does not contribute to
PGE2-induced sensitization in sensory neurons.
It remains to be determined how PGE2 maintains its
sensitization after long-term exposure to the eicosanoid.
One possibility is that EP receptors, especially EP4, become
phosphorylated on the C-terminus by GRKs [81] and that
β-arrestins are recruited to EP4 receptors following expos-
ure to PGE2 [82, 83]. β-arrestin-mediated signaling is well
characterized and includes a wide array of signaling
pathways [84], including, but not limited to, the MEK/ERK
signaling pathway [85]. Thus, activation of as yet, un-
discovered downstream signaling cascades might provide
a means for sensitization to last after long-term exposure to
PGE2. Further work is warranted to attempt to discover the
downstream signaling mediating persistent sensitization
since selective manipulation of such a pathway may prove
useful in treating chronic inflammatory pain.
Conclusions
Long-term exposure to PGE2 does not alter its ability to
sensitize sensory neurons; however, the signaling pathway
that mediates the sensitizing action of PGE2 is no longer
dependent upon activation of PKA. Indeed, long-term ex-
posure to PGE2 results in downregulation of the ability of
PGE2 or the EP4 selective agonist, L902688, to activate
PKA. This downregulation is reversible and homologous
since it does not affect the ability of PGI2 to activate PKA.
PGE2-induced sensitization after long-term exposure is
largely mediated by EP4 receptor and is independent of
both PKA and PI3K signaling pathways.
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